Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer
Authors:
- Christine H. FengCFChristine H. Feng
- Charlie M. MillerCMCharlie M. Miller
- Meaghan E. TenneyMTMeaghan E. Tenney
- Nita K. LeeNLNita K. Lee
- S. Diane YamadaSYS. Diane Yamada
- Yasmin HasanYHYasmin Hasan
- 1 November 2016
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 26 (9) , 1642-1649
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancerGynecologic Oncology, 2014
- Effect of statin on risk of gynecologic cancers: A meta-analysis of observational studies and randomized controlled trialsGynecologic Oncology, 2014
- Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor AgentsClinical Cancer Research, 2012
- Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen ExpressionThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorshipGynecologic Oncology, 2009
- Serum lipids and endometrial cancer risk: Results from the HUNT‐II studyInternational Journal of Cancer, 2009
- Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosisInternational Journal of Gynecological Cancer, 2007
- Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinomaCancer, 2006
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsNew England Journal of Medicine, 2003
- Regulation of the mevalonate pathwayNature, 1990